VitalConnect has announced the commencement of the TELESTAR-TAVR clinical study—Deployment of Telemedicine for Symptom Tracking And Decrease Readmission Rate in TAVR Patients)—monitoring patients undergoing transcatheter aortic valve replacement (TAVR) using VitalConnect’s VistaSolution LIVE technology. The trial has a primary objective of measuring the impact of remote patient monitoring (RPM) and telehealth on patient satisfaction, clinical outcomes, and readmission rates for patients.

Results of the TIDES-ACS randomised controlled trial, confirming the superior safety and sustained non-inferior efficacy of the Bio-Active Stent technology (Hexacath) at 18 months follow-up versus a drug-eluting stent, have been published.

Medtronic has announced  US Food and Drug Administration (FDA) approval of an early feasibility study (EFS) of the Intrepid transcatheter tricuspid valve replacement (TTVR) system in patients with severe, symptomatic tricuspid regurgitation. This comes on the heels of a recent Breakthrough Device Designation for the Intrepid TTVR System. The Intrepid TTVR system is an investigational device worldwide.

Researchers from the University of Minnesota, with support from Medtronic, have developed a process for multi-material 3D printing of models of the heart’s aortic valve and the surrounding structures that mimic a real patient.

Cardiac Dimensions has announced that Australia’s Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System, a right heart transcatheter mitral valve repair (TMVr) device. The device is designed to treat the primary cause of functional mitral regurgitation (FMR) in patients with mitral regurgitation grades 2+, 3+ and 4+.

Biotronik today announced European market release of the Passeo-35 Xeo percutaneous transluminal angioplasty (PTA) balloon catheter. A company press release states that, compared to other available PTA balloons, the device offers physicians improved crossability, excellent trackability, and pushability in a wide range of sizes.

According to a recent analysis, the decision to delay operative repair of abdominal aortic aneurysm (AAA) should consider both patient age and local COVID-19 prevalence in addition to aneurysm size. Furthermore, endovascular aneurysm repair (EVAR) should be considered when possible due to a reduced risk of harm and lower resource utilisation.

Boston Scientific announced that the US Centers for Medicare and Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for the Eluvia drug-eluting vascular stent system as part of the 2021 inpatient prospective payment system (IPPS).

According to a recent press release, MicroPort’s Minos ultra-low abdominal aortic aneurysm (AAA) stent graft and and Hercules low-profile thoracic aortic aneurysm (TAA) stent graft are now CE marked and available in Europe through Lombard Medical.

PQ Bypass has announced that they received breakthrough device designation from the US Food and Drug Administration (FDA) for the Detour system. The Detour system is the world’s first fully-percutaneous femoral-popliteal bypass device intended to treat extremely long, complex blockages in the superficial femoral artery (SFA).

The inaugural CX Aortic Vienna meeting will be livestreamed 8–11 September 2020 to an international, online audience, and will include registrant participation, interaction, and polling.

Concept Medical has announced the enrolment of the first patient in the FUTURE BTK (Randomised controlled trial of first sirolimus-coated balloon versus standard balloon angioplasty in the treatment of below-the-knee artery disease) trial. The index patient was successfully enrolled on 26 August 2020 in Singapore.